vs
Side-by-side financial comparison of COLONY BANKCORP INC (CBAN) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($60.1M vs $39.9M, roughly 1.5× COLONY BANKCORP INC). COLONY BANKCORP INC runs the higher net margin — 20.6% vs -92.6%, a 113.1% gap on every dollar of revenue. Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 19.6%).
Colony Bankcorp Inc is a US-based bank holding company that operates Colony Bank. It provides a full suite of personal and commercial banking services including deposit accounts, consumer and business loans, mortgage services, and wealth management solutions, primarily serving retail customers and small-to-medium enterprises across the state of Georgia.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
CBAN vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $39.9M | $60.1M |
| Net Profit | $8.2M | $-55.6M |
| Gross Margin | — | 88.1% |
| Operating Margin | — | -87.1% |
| Net Margin | 20.6% | -92.6% |
| Revenue YoY | — | 83.8% |
| Net Profit YoY | 24.1% | — |
| EPS (diluted) | — | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $39.9M | $60.1M | ||
| Q4 25 | $36.9M | $57.3M | ||
| Q3 25 | $32.8M | $51.3M | ||
| Q2 25 | $32.5M | $48.5M | ||
| Q1 25 | $30.0M | $32.7M | ||
| Q4 24 | $30.8M | $41.8M | ||
| Q3 24 | $28.6M | $33.3M | ||
| Q2 24 | $27.9M | $29.1M |
| Q1 26 | $8.2M | $-55.6M | ||
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $5.8M | $-52.9M | ||
| Q2 25 | $8.0M | $-46.6M | ||
| Q1 25 | $6.6M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $5.6M | $-43.6M | ||
| Q2 24 | $5.5M | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | 25.9% | -82.2% | ||
| Q3 25 | 22.2% | -102.6% | ||
| Q2 25 | 30.9% | -93.4% | ||
| Q1 25 | 27.6% | -143.7% | ||
| Q4 24 | 28.8% | -98.6% | ||
| Q3 24 | 24.6% | -132.0% | ||
| Q2 24 | 24.8% | -139.2% |
| Q1 26 | 20.6% | -92.6% | ||
| Q4 25 | — | -83.0% | ||
| Q3 25 | 17.7% | -103.1% | ||
| Q2 25 | 24.6% | -96.1% | ||
| Q1 25 | 22.0% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | 19.7% | -131.2% | ||
| Q2 24 | 19.6% | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $0.42 | $-0.73 | ||
| Q3 25 | $0.33 | $-0.82 | ||
| Q2 25 | $0.46 | $-0.75 | ||
| Q1 25 | $0.38 | $-0.81 | ||
| Q4 24 | $0.43 | $-0.71 | ||
| Q3 24 | $0.32 | $-0.73 | ||
| Q2 24 | $0.31 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $295.8M | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $380.4M | $122.9M |
| Total Assets | $3.7B | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $295.8M | $340.6M | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M |
| Q1 26 | — | — | ||
| Q4 25 | $258.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $248.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $380.4M | $122.9M | ||
| Q4 25 | $375.9M | $139.1M | ||
| Q3 25 | $302.3M | $148.8M | ||
| Q2 25 | $293.9M | $-11.9M | ||
| Q1 25 | $286.9M | $18.9M | ||
| Q4 24 | $278.7M | $21.7M | ||
| Q3 24 | $276.1M | $11.2M | ||
| Q2 24 | $264.7M | $39.3M |
| Q1 26 | $3.7B | $442.3M | ||
| Q4 25 | $3.7B | $480.2M | ||
| Q3 25 | $3.2B | $506.9M | ||
| Q2 25 | $3.1B | $372.7M | ||
| Q1 25 | $3.2B | $386.7M | ||
| Q4 24 | $3.1B | $392.3M | ||
| Q3 24 | $3.1B | $363.6M | ||
| Q2 24 | $3.0B | $381.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.69× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.89× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBAN
| Net Interest Income | $29.2M | 73% |
| Noninterest Income | $10.7M | 27% |
RYTM
Segment breakdown not available.
